Filing Flows › Medline (MDLN) › Guidance history
Medline (MDLN) guidance history: what it guided and what it reported
Medline gave guidance in 5 earnings releases on file since Feb 25, 2026. Its releases raised guidance 3 times and lowered it once.
Net income
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $655M (Aug 5, 2026) | — | to be reported | — |
Capital expenditures
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $500M (May 6, 2026) | — | to be reported | — |
Adjusted EBITDA
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $3.5B–$3.6B (Feb 25, 2026) → reaffirmed $3.5B–$3.6B (May 6, 2026) → lowered $3.3B–$3.4B (Aug 5, 2026) → reaffirmed $3.3B–$3.4B (Nov 4, 2026) | — | to be reported | — |
The latest quarter
Medline, Q3 2026: revenue $7.9B (+10% year over year), operating margin 6.4%, net earnings $198M, operating cash flow $1.0B. The chart follows the revenue to costs, profit and cash.
Questions
Does Medline beat its guidance?
Medline gave guidance in 5 earnings releases on file since Feb 25, 2026. Its releases raised guidance 3 times and lowered it once.
How often does Medline raise guidance?
Its earnings releases raised guidance 3 times and lowered it once since Feb 25, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.